Table 2 Characteristics of the HIV HCV patients with X4 tropic virus and with R5 tropic virus infection at baseline (BL).

From: HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection

 

Patients with X4 infection (21, 42.9%)

Patients with R5 infection (28, 57.1%)

p value

Age (years)a

53 (50–56)

52 (51–55)

0.8789

CD4+ cells/count (cells/mm3) at BLa

551 (305–610)

540 (320–655)

0.6935

Percentage of CD4+ cells at BLa

27 (20.5–37.5)

30.5 (23–35)

0.9677

CD4+ cells/count (cells/mm3) at T1a

511 (255–702)

462 (314–716)

0.8875

Percentage of CD4+ cells at T1a

30 (19–40.2)

31.5 (23–37.5)

0.8398

CD4+ cells/count (cells/mm3) at T2a

546 (355–664)b

468 (312–655)c

0.6369

Percentage of CD4+ cells at T2a

30.5 (23–35)b

30 (25.2–36.5)

0.7763

HCV-RNA at BL (IU/ml)a

722,986 (77,626–1,911,151)

1,399,163 (150,922–4,198,566)

0.4921

HCV genotype 1, n (%)

12 (57.1)

14 (50)

0.6236

HCV genotype 2, n (%)

1 (4.8)

0

0.4285

HCV genotype 3, n (%)

2 (9.6)

8 (28.6)

0.1554

HCV genotype 4, n (%)

6 (28.6)

6 (21.4)

0.5690

DAA regimen including ribavirin, n (%)b

14 (40)

21 (60)

0.5271

DAA regimen not including ribavirin, n (%)c

7 (50)

7 (50)

 

Residual viremia, n (%)

13 (61.9)

22 (78.6)

0.2059

Modified ART, n (%)

12 (57.1)

13 (46.4)

0.4624

HIV DNA in patients with residual viremia, (copies/PBMC)a

127 (90–245)

138 (68–261)

0.6572

HIV DNA in patients with suppressed viremia (copies/PBMC)a

36 (3–47)

116 (42–154)

0.1538

  1. aMedian and interquartile range.
  2. bPercentage calculated with respect to the 35 patients treated with a DAA regimen including ribavirin.
  3. cPercentage calculated with respect to the 14 patients treated with a DAA regimen not including ribavirin.
  4. DAA direct-acting antivirals, PBMC peripheral blood mononuclear cells, ART antiretroviral therapy, T1 week 12 of anti-HCV treatment, T2 week 24 after HCV treatment started.
Back to article page